Stay updated on Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial
Sign up to get notified when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.

Latest updates to the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoChange DetectedThe page has undergone significant content removal regarding a clinical study on risankizumab for psoriasis, including detailed study objectives, methodology, and inclusion/exclusion criteria. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference11%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.